About company

 
   JSC “"Biosintez”", a SUN PHARMA company – is  one of Russia's largest pharmaceutical companies. Sun Pharma is the fifth largest global generic pharmaceutical company with global revenues of US$ 4.3 billion. With presence in more than 150 countries, Sun Pharma is known for its high quality, speciality generic medicines trusted by patients & health professionals worldwide.JSC “Biosintez” today sells products in 12 countries of the CIS. The history of JSC "Biosintez" begins in 1955, when on the outskirts of the city of Penza several buildings of the future plant  began to grow . After 4 years, the first production enterprise was launched in October 1959 - biomitsin antibiotic and vitamin B12. This day is stated to be  the birthday of the plant.
   During  next years, the plant intensively developed by the production of substances of microbiological synthesis, and has become one of the largest companies in the pharmaceutical industry of the Soviet Union. Substance of oleandomitsine, tetracycline, Nystatin, geliomitsine, fuzidine, levorine, griseofulvine, Riboxinum and other preparations were of high quality and stability. Plant development project involved not only the production of substances, but  drugs in various dosage forms as well, and the first of them - the tablet was mastered just two years after the birth of the company, in 1961.
  1971 year  marked the beginning of the production of sterile dosage forms - in this year complexes for the production of infusion solutions in glass bottles and powders for injection were discovered.
In 1986 new complex for the production began to function and gradually build up the capacity of substances of animal and vegetable raw materials: insulin, heparin, pancreatic, valerian extract, sodium nucleate.
In 1998 the list of sterile dosage forms was supplemented injectable solutions in ampoules.
In 1996  the company opened another new trend - the production of soft medicinal forms: ointments, creams, gels and suppositories aluminum tubes.
   Due to  substance market fall in Russia in the mid-90s of the last century, JSC "Biosintez" was forced to fight for the survival of the company and the team, and only a sharp increase in the range of manufactured  drugs (three times during 5 years), has allowed to keep its position in the pharmaceutical market .
Quality of products has always been the main objective of the company, and in 2002 the new laboratory  for complex quality control department, certified by Russian Ministry of Health on the technical competence was built .
Starting in  2005, factory  began an active process of modernization major industries.
So, in 2006, in accordance with the technical re-equipment plan a new section of filling and packaging of tablets in blisters put into operation
   In 2007 was  organized the production of powders for injection cephalosporin, certified in accordance with EU GMP requirements.
Despite the sharp decline in the production of substances, JSC "Biosintez" continues to produce a number of them, both for self-use and for sale for export to non-CIS countries. A particular demand substance antibiotics fusidic acid and sodium fuzidinu which  production is certified for compliance with GMP experts from the European Directorate for the quality of medicines (EDQM), and the quality is confirmed by certificates of conformity to the requirements of the European Pharmacopoeia. During  the period from 2009 to 2013 The Ministry of Industry and Trade of the Russian Federation has repeatedly recognized JSC " Biosintez " as the  winner of the competition for the title "Best Exporter" of the pharmaceutical industry, and over the years the company has been awarded the title of "most dynamic exporter" of the pharmaceutical industry, "Best exporter in the country CIS. " Our history is written with today's business.
   In the period from 2012 to 2014 in the company as part of a large-scale investment project "Modernization of the production of medicines “ on JSC " Biosintez “passed complete reconstruction and modernization of all production sites of the enterprise.